← All trials
NCT02301286
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2014
- Primary completion
- Sep 1, 2022
- Completion date
- Sep 1, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 1588
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Leiden UniversityLead sponsor
- Leiden UniversityOverall official - principal investigator
- Leiden UniversityReponsible party - principal investigator
- Dutch Colorectal Cancer GroupCollaborator
- Fonds NutsOhraCollaborator
- Innovatiefonds ZorgverzekeraarsCollaborator
- Stichting voor Patienten met Kanker aan het SpijsverteringskanaalCollaborator
- Stichting Geriatrische Oncologie NederlandCollaborator
- Erasmus University RotterdamOverall official - principal investigator
- Government of BelgiumCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.